open access

Vol 21, No 3 (2016)
Review
Published online: 2016-05-01
Submitted: 2015-06-15
Get Citation

Current treatment options of brain metastases and outcomes in patients with malignant melanoma

Jadwiga Nowak-Sadzikowska, Tomasz Walasek, Jerzy Jakubowicz, Paweł Blecharz, Marian Reinfuss
DOI: 10.1016/j.rpor.2015.12.001
·
Rep Pract Oncol Radiother 2016;21(3):271-277.

open access

Vol 21, No 3 (2016)
Review
Published online: 2016-05-01
Submitted: 2015-06-15

Abstract

The prognosis for patients with melanoma who have brain metastases is poor, a median survival does not exceed 4–6 months. There are no uniform standards of treatment for patients with melanoma brain metastases (MBMs). The most preferred treatment approaches include local therapy – surgical resection and/or stereotactic radiosurgery (SRS). The role of whole brain radiotherapy (WBRT) as an adjuvant to local therapy is controversial. WBRT remains a palliative approach for those patients who have multiple MBMs with contraindications for surgery or SRS, or/and poor performance status, or/and very widespread extracranial metastases. Corticosteroids have been used in palliative treatment of MBMs as relief from symptoms related to intracranial pressure and edema. In recent years, the development of new systemic therapeutic strategies has been observed. Various modalities of systemic treatment include chemotherapy, immunotherapy and targeted therapy. Also, multimodality management in different combinations is a common strategy. Decisions regarding the use of specific treatment modalities are dependent on patient's performance status, and the extent of both intracranial and extracranial disease. This review summarizes current treatment options, indications and outcomes in patients with brain metastases from melanoma.

Abstract

The prognosis for patients with melanoma who have brain metastases is poor, a median survival does not exceed 4–6 months. There are no uniform standards of treatment for patients with melanoma brain metastases (MBMs). The most preferred treatment approaches include local therapy – surgical resection and/or stereotactic radiosurgery (SRS). The role of whole brain radiotherapy (WBRT) as an adjuvant to local therapy is controversial. WBRT remains a palliative approach for those patients who have multiple MBMs with contraindications for surgery or SRS, or/and poor performance status, or/and very widespread extracranial metastases. Corticosteroids have been used in palliative treatment of MBMs as relief from symptoms related to intracranial pressure and edema. In recent years, the development of new systemic therapeutic strategies has been observed. Various modalities of systemic treatment include chemotherapy, immunotherapy and targeted therapy. Also, multimodality management in different combinations is a common strategy. Decisions regarding the use of specific treatment modalities are dependent on patient's performance status, and the extent of both intracranial and extracranial disease. This review summarizes current treatment options, indications and outcomes in patients with brain metastases from melanoma.

Get Citation

Keywords

Melanoma; Brain metastases; Radiotherapy; Surgery; Systemic therapy

About this article
Title

Current treatment options of brain metastases and outcomes in patients with malignant melanoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 21, No 3 (2016)

Pages

271-277

Published online

2016-05-01

DOI

10.1016/j.rpor.2015.12.001

Bibliographic record

Rep Pract Oncol Radiother 2016;21(3):271-277.

Keywords

Melanoma
Brain metastases
Radiotherapy
Surgery
Systemic therapy

Authors

Jadwiga Nowak-Sadzikowska
Tomasz Walasek
Jerzy Jakubowicz
Paweł Blecharz
Marian Reinfuss

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl